Get started

Biotech

NGM, The Little NASH Stock That CouldNGM I remain bullish on NGM's near-term price performance. Seventy-one percent of the outstanding shares are held by insiders and institutions. The largest shareholders being The Column Group L.P, David Goeddel (managing partner at The Column Group), and Peter Svennilson who are lauded in the biopharma industry. Goeddel's last company (Tularik) was sold to Amgen for $1.3 B in 2003. Merck also took a stake worth $450 M before NGM went public which included a 15% equity stake. The key point here is that these are not your everyday stakeholders. They are activists as well as investors. They are in for the long haul and will continue to buy as long as shorts try to bring NGM down as shorts have done to every other NASH stock. Since October 11th there have been eleven Form-4s. If you look back further you'll see many pages of insider buys since NGM's IPO earlier this year. Today (11/6/19) four more Form-4s came out showing that the insiders above collectively purchased ~$420K worth of stock this week. Buying support like this from the likes of this caliber of scientists and investors sends a strong message to short-sellers. Moreover, it will stoke the interest of investors on the sidelines. The fact that from 1Q19 to 2Q19 the number of hedge funds invested in NGM went from 0 to 10 supports this assumption. There are also multiple intermediate-term catalysts. In November of 2018 MRK reported positive phase 1b proof of concept data which showed that once-monthly NGM313 had an efficacious effect on insulin-resistant (i.e diabetic) NASH patients. This led to MRK exercising its option to license NGM313 (now MK-3655) from NGM in January 2019. The initiation of the phase 2 study for MK313 could happen at any time and could be catalytic for NGM. Finally, top-line data from NGM's phase 2 NASH study is expected in the first quarter of 2020. In my opinion, this data readout has the potential to propel NGM like Constellation Pharmaceuticals (CNST) which closed up 90% today (11/6/19) after announcing promising phase 2 data. To this point, CNST is another stock that The Column Group has a significant stake in (6.2 million shares, 18% ownership). Whereas in NGM they own 16.5 M shares (25% ownership stake). I don't know about you but I concentrate my capital on my top picks. A final aspect of my thesis is that shorts have not covered since there latest attacks. Based on data available on iborrow, the number of shares available to borrow went down to 20K this week from 100K last week. Assuming I am correct, and shorts can not successfully bring NGM down, the combination of shorts covering and longs buying will fuel the next leg up. As I discussed above the float is locked up and sits at 22 M. Under these conditions, we could see a strong move up.
NLong
by MS_Money_Moves
Potential Reversal Marker TherapeuticsMRKR Entered MRKR at $4.01 on Friday (11/1/19) and am monitoring for a sustained trend reversal. Watching for SP to bounce off $4.10, or if that does not hold, $4.01. If it does not reverse here I think it'll consolidate between $3.83 and $4.32. A reversal would coincide with a run-up into Q3 earnings which should be sometime this month and phase 2 data in Ovarian Cancer expected this quarter. Closing over $4.32 would be a good confirmation of a trend reversal. RSI and CCI on the daily support the stock is building momentum IMO.
NASDAQ:MRKRLong
by MS_Money_Moves
NUVA BUYBUY signal at 65.73$. Timeframe - 1 week. Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. If you want to see more history of this strategy, I able to show you if you request me. It's one of two signal algo for NUVA. ATTENTION this strategy may has downtrend about 10-15%, so you can split your buy order, that you have not big downtrend. __________________________________________________________________________ You can use the signals independently or like indicator of trends together with other indicators in your trading strategy. Know that the success of your strategy that based on those signals depends from your money management and the additional conditions that you make in these strategies. You use these signals inside your strategies at your own risk. The chart shows the last trades on the product + the last signal. I have several strategies for different products, and I want to show you proof of it works on history, and you will be able to see it, when returns to that profile. Therefore, subscribe and watch for that profile. The signals rare but useful.
NLong
by price_and_time
Can TTNP Actually Gap Fill Or Is It Forever Going To Trade Here?TTNP has been catching attention on volume scans this month. Ever since gapping down on October 16, the daily action is noticeably greater than before. But is this a good or bad sign for the penny stock? Currently trading around $0.20. OS is around 17 million so it's not the biggest out there but not the smallest either. Titan Pharmaceuticals is a company that develops treatments for chronic diseases using its ProNeura platform. Titan announced a $9 million public offering a week ago. While the company’s stock took a price hit due to the per-share pricing of the offering it is okay.It is okay because ever since the company did this, a surge of volume has entered the stock. In addition to this, analysts are taking notice of the company too. Maxim Group upgraded TTNP stock from “HOLD” to “BUY” this week and gave a $1 price target. ABOUT TTNP Titan Pharmaceuticals Inc is a specialty pharmaceutical company. It is engaged in the development of pharmaceutical products. Its product pipeline consists of Probuphine for Opioid addiction, Ropinirole for Parkinson's disease, Triiodothyronine (T3) for hypothyroidism. It generates revenue principally from collaborative research and development arrangements, technology licenses, and government grants. QUOTE SOURCE: 4 Penny Stocks Catching Biotech Investors By Surprise
NASDAQ:TTNP
by PennyStocks101
Gartley + Additional data release todayFriday, October 11, 2019 ADVM is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, ADVM is set to present additional clinical data for the first cohort of patients (n=6) in the OPTIC phase 1 clinical trial of ADVM-022, intra-vitreal injection gene therapy in wet age-related macular degeneration (wet AMD) at the Retina Sub-specialty Day Program of the American Academy of Ophthalmology (AAO) 2019 Annual Meeting in San Francisco, CA. NEXT EARNING: Nov 11, 2019 MARKET CAP: $333.254 Million Technical Analysis: -Bullish Gartley pattern -Fibonacci 876 retracement is an important reversal level in high volatility trades. -Our MS Signal oscillator indicating RSI moving higher and now being a potential good time to buy for a bounce. -MS CCI Squeeze also indicating that bulls are re-gaining control (over mid-line suggests potential squeeze incoming) Please like, share, and follow so I can continue finding awesome trades. Check out MS Money Trade Ideas for pre-researched trades to add to your watchlist!! Thanks in advance. Disclosure: I am long ADVM. I may buy or sell within the next 72 hours. This is not a recommendation to buy or sell. Please do your homework before investing.
NASDAQ:ADVMLong
by follow_the_money